Verrica Q3 revenue halves to $6.9 million as YCANTH sales climb 58%
GlobeNewswire · · AI-summarised by FinFlash
Verrica Pharmaceuticals reported third-quarter total revenue of $6.9 million, down from Product growth is solid but the stock hinges on common-wart trial data due in Q1 2027 and mid-2027; funding runway reduces near-term dilution risk. Published information may change. Summaries can contain errors; check the original source. Educational information only, not investment advice.So What?
Understand the context